Gilead Keeps Focus On HIV, Long-Acting Drugs And Growth Through Oncology
Three Years On, Strategy Under CEO O’Day Is Unchanged
Executive Summary
Even with top-seller Biktarvy and its preventive therapy, Descovy, protected beyond this decade from generics, Gilead is investing aggressively in long-acting HIV candidates and its oncology pipeline.
You may also be interested in...
Gilead’s Kite Hopes To Reinforce Commercial CAR-T Lead With Yescarta Data
The company presented results from the ZUMA-7 trial at ASCO for the CAR-T therapy in the curative setting of large B-cell lymphoma.
Deal Watch: Gilead Grows Oncology, Inflammation Pipeline With XinThera Buy
The XinThera deal gives Gilead multiple PARP1 and MK2 inhibitors. Also, Roche licenses a HER2 kinase inhibitor from Zion, Amgen partners with TScan in Crohn’s disease and Baxter sells the last of its biopharma operations – a CDMO business – for $4.5bn.
Gilead Reports 61 Clinical Programs Under Way, With Over 20 In Phase III
Excluding sales declines due to Veklury, Gilead said its year-over-year sales grew 15% in the first quarter, with HIV drug Biktarvy serving as the biggest driver.